TRUSTED LEGAL COUNSEL
Wisner Baum serves as co-lead trial counsel in the Gardasil MDL. We plan to go to trial in early 2025.
PROVEN TRACK RECORD
Wisner Baum has earned more than $4 billion in verdicts and settlements for clients across all practice areas. We have the resources and experience to take on various opponents and win.
History of Success
Our team has a strong reputation for successfully litigating against Big Pharma.
Leaders in the Zantac Litigation
Wisner Baum’s managing partner R. Brent Wisner serves as co-lead trial counsel for plaintiffs with Zantac lawsuits in California and Delaware state courts.
People who developed cancer after taking Zantac (generic: ranitidine) may choose to file a Zantac lawsuit against the drug manufacturers to recover financial compensation for past, present, and future medical bills, lost wages, and other damages.
Check to see if you are eligible to pursue a Zantac lawsuit by filling out this confidential case evaluation form.
Independent laboratory testing found that one ranitidine 150 mg tablet produced 304,500 nanograms (ng) of a cancer-causing substance called N-Nitrosodimethylamine (NDMA), an amount that greatly exceeds the U.S. Food and Drug Administration’s (FDA) daily acceptable intake limit of 96 ng.
Zantac lawsuits began after the FDA confirmed that ranitidine contains NDMA. On April 1, 2020, the FDA requested a market withdrawal for Zantac ranitidine drugs, stating that NDMA in some ranitidine medications “increases over time and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels…”
The FDA, the Environmental Protection Agency (EPA), and the World Health Organization (WHO) all classify NDMA as a cancer-causing substance.
Several manufacturers, including Sanofi and GlaxoSmithKline (GSK) have issued voluntary Zantac recall announcements, citing safety concerns.
Wisner Baum serves on the plaintiffs’ leadership for Zantac cancer cases filed in California State Court and Delaware State Court. We are preparing for the first Zantac trial, which will take place on November 13, 2023 in Superior Court of California, Alameda County.
In June of 2023, Zantac attorneys Jennifer Moore of the Moore Law Group and R. Brent Wisner of Wisner Baum negotiated a confidential Zantac settlement in the case of James Goetz v. GlaxoSmithKline, LLC, Superior Court of California, Alameda County. The Zantac settlement was reached weeks before the case was scheduled for trial. It would have been the first to go before a jury.
Daubert Hearing Begins in Delaware Zantac Cancer Litigation
Can I File a Zantac Lawsuit in 2023?
Four Lawyers to Lead Over 75K Cases in Delaware Zantac Cancer Litigation
CA Judge Denies GSK’s Bid to Toss Zantac Lawsuit, Trial Set for July
Zantac Cancer Lawyers File Lawsuits for Over 7,000 People in All 50 States
Zantac Attorneys Sue FDA to Force Release of ‘Flawed’ Study Docs
Can I File a Zantac Lawsuit Without Proof of Purchase?
Is Zantac Back on the Market?
Which Cancers Qualify for the Zantac Lawsuit?
Our law firm is currently accepting Zantac cancer cases on behalf of people who took the drug for at least one year and developed the following cancers:
- Bladder cancer
- Esophageal cancer
- Gastric cancer / stomach cancer
- Liver cancer
- Pancreatic cancer
- Prostate cancer
- Breast cancer
- Lung cancer
- Colon cancer
Those who are eligible and meet certain requirements must submit their claim within a time limit called the statute of limitations. We advise anyone who is considering a Zantac lawsuit to speak with an attorney as soon as possible to ensure that they are not time-barred from pursuing a claim.
Please note that Zantac lawsuit eligibility may change at any time in accordance with court orders.
What is the Current Status of the Zantac Lawsuit?
- February 7, 2024: Another Zantac lawsuit in California state court has culminated in a confidential settlement weeks before trial. Plaintiff David Browne’s case adds to a series of Zantac settlement agreements over the past eight months. In October of 2023, GSK announced that it had settled four cases, including one that was scheduled for trial in November. Prior to that, attorneys negotiated a Zantac settlement for plaintiff James Goetz roughly a month before trial was set to begin.
Wisner Baum managing partner R. Brent Wisner serves on the plaintiffs’ leadership in the Zantac litigation in California state court. He and co-counsel Jennifer Moore have now secured Zantac settlement agreements in several cases as trial dates loomed.
In Delaware, we are still awaiting Judge Medinilla’s ruling on Daubert. We are optimistic that our experts will be permitted to share their opinions with a jury, and that the litigation will proceed.
- January 19, 2024: A Daubert hearing in the Delaware Zantac litigation will take place on January 22 – 25 before the Hon. Judge Vivian L. Medinilla.
At a Daubert hearing, legal teams for the plaintiffs and the defense present their experts to educate the court on the science behind both sides of the alleged Zantac cancer connection. The plaintiffs must demonstrate that they have scientific evidence to back their claims that Zantac causes cancer. Judge Medinilla will evaluate whether the methodologies expert witnesses relied on to arrive at their conclusions are backed by sound science. If the judge determines those methodologies are valid, our expert witnesses will be allowed to testify in court and the Zantac cancer cases can proceed to trial.
The hearing will begin at 9:00 a.m. local time at the Leonard L. Williams Justice Center, 500 North King Street, Wilmington, Delaware, 19801.
- January 12, 2024: As we prepare for the first Zantac trial next month, we are in the process of finalizing the schedule(s) for the next round of bellwether trials here in California. We will have more information in the coming weeks. Our firm will also have some news on the Delaware Zantac litigation by the end of January.
- December 1, 2023: The first Zantac trial is tentatively scheduled to take place in February of 2024 in Alameda County, California. The case, part of the California Zantac JCCP (Ranitidine Product Cases, JCCP No. 5150), will be for a claimant who alleges Zantac caused their bladder cancer. Jennifer Moore of the Moore Law Group will co-lead the trial team with R. Brent Wisner of Wisner Baum. More details to come.
Multiple lawyers recommended Wisner Baum to me and I have been consistently impressed with the quality of their work.- Best Law Firms Survey
Wisner Baum are not only amazing attorneys but more importantly, they are activists. They are about changing the systems which got us into trouble in the first place. They understand their role in the process of making change.- Kim Witczak
The Wisner Baum firm has some of the top legal minds in the country; they are driven, determined, trustworthy, ethical and passionate.- From Best Lawyers® Best Law Firms
Zantac Lawyer Appointed to Leadership Role in Litigation
Zantac lawyer R. Brent Wisner serves as Co-lead Plaintiffs’ Liaison Counsel for the Ranitidine Product Cases, also known as the Ranitidine (Zantac) Judicial Council Coordinated Proceedings (JCCP 5150) in California Superior Court for the County of Alameda. He was also appointed co-lead trial counsel in the Zantac (Ranitidine) Products Liability Litigation (Civil Action No. N22C-09-101 ZAN) in Delaware Superior Court. As of August 2023, there are nearly 85,000 cases filed in California and Delaware.
Zantac Lawyers with Billions in Verdicts and Settlements
- Boehringer Ingelheim Pharmaceuticals, Inc., a subsidiary of Boehringer Ingelheim Corporation
- Sanofi US Services Inc., a wholly owned subsidiary of Sanofi S.A.
- Pfizer, Inc.
- GlaxoSmithKline, LLC
How We Can Help With Your Zantac Lawsuit
The trial-ready team of attorneys at Wisner Baum intend to hold the makers of Zantac accountable for allegedly concealing the ranitidine cancer link. With more than $4 billion in verdicts and settlements won across all practice areas, we have the experience and track record needed to secure maximum compensation for our clients.
We have filed Zantac lawsuits alleging the drug maker defendants have known for decades that the ranitidine molecule is capable of producing staggering amounts of the carcinogen NDMA when ingested as directed. Rather than warning people about the Zantac cancer risk, the drug makers willingly chose to put profit over people.
Our clients would never have purchased or used this drug had the manufacturers properly disclosed potentially fatal Zantac side effects. Outraged by the recklessness of these companies, we intend to hold them accountable for the damage they have caused.
Wisner Baum Zantac Attorneys Are in Active Litigation. If You Were Diagnosed with Cancer After Taking Zantac, You May be Eligible to Pursue Compensation in a Ranitidine Lawsuit. Contact Us Online or Call (855) 948-5098 to See if You Qualify.
Join the Zantac Cancer Lawsuit
Wisner Baum is one of the leading firms in the Zantac litigation. In practice for nearly 50 years, our firm has earned a reputation for winning big cases against big companies. One of our greatest successes in litigation shares similarities to the Zantac litigation. Our lawsuits against Monsanto (now part of Bayer) involved allegations that a consumer product causes cancer (non-Hodgkin’s lymphoma).
At trial, co-lead counsel R. Brent Wisner delivered the opening and closing statements before the jury. Wisner and his colleagues earned a $2.055 billion jury verdict* for our clients, one of the largest personal injury jury verdicts in U.S. history. A similar case resulted in a $289.2 million jury verdict* on behalf of our client, the second-largest jury verdict in the state of California for 2018.
Put your case in the hands of an experienced legal team that understands what it takes to earn the results clients deserve.
*Jury verdicts later reduced
Zantac (ranitidine) was taken off the market because the drug contains unacceptable levels of N-Nitrosodimethylamine (NDMA), which is a substance known to cause cancer. Testing of ranitidine drugs showed levels of NDMA above the FDA’s acceptable daily intake limit of 96 nanograms (ng) per day. For example, testing from Connecticut-based online pharmacy Valisure detected NDMA in excess of 3,000,000 ng per tablet when analyzing ranitidine products.
Valisure tests medications for consistency and quality issues. During testing, the company discovered extremely high levels of NDMA “in every lot tested, across multiple manufacturers and dosage forms of the drug ranitidine.”
Valisure’s finding was consistent with studies from Stanford University and elsewhere, which found that NDMA in Zantac was likely due to the “inherent instability” of the ranitidine molecule.
“There’s no acceptable cancer risk for a drug like this,” said David Light, CEO of Valisure.
Valisure reported its findings to the FDA in June of 2019. Three months later, the company filed a citizen’s petition urging the FDA to issue a Zantac recall and suspend all sales:
“Combined with other data from Valisure and the scientific works of Stanford University and others, the evidence presented shows this instability and the resulting NDMA occurs in the conditions representative of those in the human body and builds a compelling case for ranitidine being a likely human carcinogen.”
On Jan. 2, 2020, research laboratory Emery Pharma filed a citizen’s petition of its own noting that ranitidine is a time and temperature-sensitive pharmaceutical product that develops into NDMA when exposed to heat. In a press release, Emery Pharma noted:
“Exposure to high temperatures is a common occurrence during transportation and storage, and is of specific concern to ranitidine as there currently are no requirements for the drug to be shipped in temperature-controlled conditions and/or stored under refrigeration.”
Ranitidine is a very unstable molecule. On one side, you have the N (Nitroso). On the other side, you have the DMA (Dimethylamine). When the molecule is exposed to heat, various biological processes in the stomach, and enzymatic reactions throughout the body, it shears apart and reconstitutes as NDMA. But the formation of NDMA is not limited to the reaction in human stomach. Ranitidine can turn into NDMA in the pill bottle itself. In fact, our Zantac lawsuits allege that the drug manufacturers for decades had this problem where ranitidine turned yellow in storage. If it’s yellow, that’s NDMA. They claim they had no idea why this was the case, but our lawsuits say otherwise—they knew.” – Zantac Attorney R. Brent Wisner
If you took Zantac and developed cancer, it is in your best interest to speak with an experienced personal injury attorney about filing a Zantac lawsuit. Based in Los Angeles and serving clients nationwide, our attorneys at Wisner Baum have vast experience holding big corporations accountable for concealing the true dangers of consumer products.